Q4 2023 Earnings Summary
- Afya anticipates margin expansions across all three segments in 2024, driven by operational leverage, strong demand, and efficiency initiatives like the zero-budget project. They project a 12% top-line growth and 16% bottom-line growth year-over-year, with undergrad segment growing 10%, continued education 20%, and digital services 30%.
- The company is experiencing strong demand for its medical programs, with the candidate per seat ratio increasing to almost 6, higher than before the pandemic. Additionally, tuition prices are expected to increase by over 5.8%, contributing to revenue growth.
- Afya's digital services B2B contracts grew more than 60% organically in 2023, due to expanding relationships with pharmaceutical companies and new product offerings like X insights. This trend is expected to continue and boost growth in 2024.
- Regulatory uncertainties and delays related to the Mais Médicos program and Supreme Court injunctions may impact Afya's growth plans, as the schedule for new proposals has been postponed to 2025, creating uncertainty in the expansion of new campuses. , ,
- The potential influx of 9,000 to 10,000 additional medical seats over the next 5 to 6 years could increase competition, impacting Afya's ability to maintain pricing and market share in the long term.
- Recent changes in the Mais Médicos program limit each institution to offer for only one state, reducing Afya's bidding opportunities from 36 to 23 campuses, which may constrain the company's expansion plans and future growth potential.
-
Margin Outlook
Q: What is the outlook for margins in 2024?
A: Management expects margin expansions across all three segments in 2024 due to operational leverage and efficiency gains. In undergrad, the full integration of UNIMA/FCM Jaboatão will contribute to higher margins. Continued education margins will expand as new campuses are filled, improving efficiency. Digital services will see margin growth from expanding services, increased B2P users, and new B2B contracts. The adjusted EBITDA is guided to grow 16% year-over-year, indicating overall margin expansion. -
Digital Services Growth
Q: Why did B2B digital services accelerate in Q4?
A: B2B digital services grew over 60% organically due to increased contracts with pharmaceutical companies for marketing campaigns using Afya's apps and sites to reach physicians. New recurring products launched at the end of 2023 are expected to contribute to additional growth in 2024. -
M&A Pipeline
Q: What's the status of potential M&A activities?
A: Management is actively pursuing M&A opportunities within their niche target market, focusing on institutions with over 60% of revenues from medicine. They aim for acquisitions with unlevered IRR above 20% and expect future deal multiples to be below their last acquisition, indicating potential upside in current multiples. -
Mais Médicos Program Impact
Q: How will new seat authorizations affect competition?
A: The potential addition of 9,000 to 10,000 medical seats over 5–6 years through the Mais Médicos program and injunctions could increase competition. However, approvals depend on the Ministry of Education and the Supreme Court's final decisions. -
Competitive Environment
Q: Any significant changes in the competitive environment?
A: The candidate per seat ratio increased to almost 6 candidates per seat, higher than pre-pandemic levels, indicating strong demand. Price increases averaged over 5.8%, surpassing the initial expectation of 4.9%. -
Medcel Strategy Acceptance
Q: How was the acceptance of Medcel's new strategy?
A: In Q4, Medcel saw a higher intake and sales volume for residency programs compared to last year, marking the first such increase in two years. Other brands like CardioPapers also grew over 30% year-over-year, contributing to digital operations and margin leverage.